For frequent travelers or those in shared living situations, that simplicity matters
If that's you, waiting for retatrutide is the right call: Severe obesity (BMI 40)
Effective January 1, 2026, Medi-Cal Rx is excluding coverage for GLP-1 medications prescribed for weight loss: [12] Wegovy, Zepbound, Saxenda: Completely removed from the Contract Drugs List for weight loss Ozempic, Mounjaro, Rybelsus: Restricted to Type 2 diabetes onlyweight loss claims will auto-deny Existing prior authorizations end December 31, 2025 Exceptions: Members under age 21 may still qualify via EPSDT Non-weight-loss indications (Zepbound for OSA, Wegovy for cardiovascular) may still get PA approval This does NOT affect Kaiser commercial or employer-sponsored plansonly Medi-Cal members
Moreover, there was no difference in weight changes between exenatide and abiglutide, and both were shown to exhibit remarkable weight loss effects (174)
Understanding the clinical significance of each category helps patients and prescribers evaluate the platform's risk profile
Membership, shipping, and all supplies are included for compounded meds